In response to rapidly growing demand for Lexogen’s products from customers in the US, we decided to open our first subsidiary, Lexogen, Inc., in New Hampshire. Now our kits can be delivered overnight to any destination in the continental US.
Though our priority stays unchanged – to enable complete transcriptome sequencing by developing unique and innovative library prep solutions for NGS - we are also committed to ensure fast access to our products for a worldwide user base. We have already successful distribution partnerships in 30 countries, and our direct presence in the US beneficially compliments this global coverage.
Lexogen is an ambitious biotech start-up with unique proprietary expression profiling technologies that enable detailed profiling of the complete transcriptome as well as individual full length RNAs of interest.
Lexogen was founded in 2007 and is funded by both private capital and public funds. Lexogen is supported by the Austrian Research Promotion Agency FFG, the Austria Wirtschaftsservice AWS, INiTS and the Wirtschaftsagentur Wien.
Lexogen employs 28 scientists and staff and is based in Vienna, Austria.